GlycoPharma Holding ApS: Financial statements 2022
CVR: 39691558
Source: annual report 2022, Danish Business Authority
01/07/2021 – 30/06/2022
GlycoPharma Holding ApS (CVR 39691558) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -8,098 and a net result of DKK -7,287 compared with DKK -8,120 the year before. Equity in the 2022 report amounted to DKK 406,648. The solvency ratio was 28.4%.
- Gross Profit
- DKK -8,098
- Profit/Loss
- DKK -7,287
- Equity
- DKK 406,648
- Total Assets
- DKK 1,432,950
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -8K | -7K | 407K | - |
| 2021 | - | -12K | -8K | 414K | - |
| 2020 | - | -7K | -618 | 314K | - |
| 2019 | - | -8K | -6K | 315K | - |
Official annual report
Keep an eye on GlycoPharma Holding ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringAbout GlycoPharma Holding ApS
GlycoPharma Holding ApS is a Danish company of the type Anpartsselskab based in Odense SØ, founded in 2018. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Anders Boysen. The company's owners include SCIENCE VENTURES DENMARK A/S, Boysen Bio ApS and Zahle Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -12,525 and a net result of DKK -12,441 compared with DKK -15,360 the year before. Equity in the 2025 report amounted to DKK 684,140.